Trial Profile
A third phase III safety and pharmacokinetics study to of HTX-011
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2021
Price :
$35
*
At a glance
- Drugs Bupivacaine/meloxicam (Primary)
- Indications Postoperative pain
- Focus Adverse reactions; Pharmacokinetics; Registrational
- 11 Jan 2021 According to a Heron Therapeutics media release, the New Drug Application (NDA) was resubmitted to the U.S. FDA for HTX-011, for the management of postoperative pain. This resubmission is under review. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 12, 2021.
- 19 Feb 2020 According to an Heron Therapeutics media release, the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for HTX-011 by up to three months. The new PDUFA goal date is June 26, 2020.
- 14 Aug 2017 New trial record